# Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

> **NCT06354387** · PHASE1 · COMPLETED · sponsor: **China Medical University Hospital** · enrollment: 5 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Alectinib (Alecensa), Nivolumab (Opdivo)

## Key facts

- **NCT ID:** NCT06354387
- **Lead sponsor:** China Medical University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-16
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06354387

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06354387, "Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06354387. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*